- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN) | 4 | Insider Monkey | ||
| 10.06. | Day One Biopharmaceuticals, Inc.: Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development | 5 | GlobeNewswire (USA) | ||
| 03.06. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.05. | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | 289 | GlobeNewswire (Europe) | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen | |
| 06.05. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.04. | Day One Biopharmaceuticals, Inc.: Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 | 8 | GlobeNewswire (USA) | ||
| 03.04. | H.C. Wainwright maintains Buy on Day One Biopharmaceuticals | 10 | Investing.com | ||
| 06.03. | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 26.02. | Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright | 8 | Investing.com | ||
| 25.02. | Day One Biopharmaceuticals GAAP EPS of -$1.02 misses by $0.29, revenue of $131.16M beats by $8.64M | 2 | Seeking Alpha | ||
| 25.02. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.02. | Day One Biopharmaceuticals, Inc.: Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 | 7 | GlobeNewswire (USA) | ||
| 23.01. | Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? | 13 | Insider Monkey | ||
| 13.01. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.01. | Day One Biopharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.10.24 | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | 415 | GlobeNewswire (Europe) | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
| 30.07.24 | Day One Biopharmaceuticals, Inc.: Day One Reports Second Quarter 2024 Financial Results and Corporate Progress | 393 | GlobeNewswire (Europe) | Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| AMGEN | 237,00 | +0,11 % | Amgen-Aktie mit Kursverlusten (237,1233 €) | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
| NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| BIOGEN | 108,05 | +0,32 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
| VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
| BIOCRYST PHARMACEUTICALS | 7,834 | -1,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million | -Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones-
-BioCryst plans to use proceeds to... ► Artikel lesen | |
| TEMPUS AI | 56,44 | -0,67 % | Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? | ||
| SAREPTA THERAPEUTICS | 14,575 | -0,21 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny | ||
| CARDIOL THERAPEUTICS | 1,304 | +8,49 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| EXELIXIS | 37,080 | -0,59 % | ROUNDUP/Aktien New York: Entspannt nach US-Militärschlag und positiven Daten | NEW YORK (dpa-AFX) - Angesichts der bislang überschaubaren ökonomischen Auswirkungen des US-Militärschlags gegen den Iran sind die Anleger an den US-Börsen am Montag recht gelassen geblieben. Zudem... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock |
Das Unternehmen DAY ONE BIOPHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-0,15 %) liegt der Kurs bei 6,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.